In contrast, HER2-positive and TNBC subtypes are invasive breast cancers that are commonly associated with a poorer prognosis, a higher rate of distant recurrence, and the shortest overall survival rate of all breast cancers. This evidence concerns the gene ERBB2 and breast carcinoma.